Atossa Therapeutics

ATOSPhase 2

Atossa Therapeutics is dedicated to transforming breast cancer care through patient-centric solutions and breakthrough science. Its primary focus is the development of (Z)-endoxifen, a novel SERM designed to be significantly more potent than existing options, with potential applications from prevention to metastatic treatment. As a publicly traded company, Atossa is advancing its clinical programs to target high-need breast cancer indications where current therapies are inadequate. The company's mission is to improve outcomes for the millions of women affected by breast cancer worldwide.

Market Cap

$105.9M

Focus

Drug DeliverySmall Molecules

ATOS · Stock Price

USD 12.3010.80 (-46.75%)

Historical price data

AI Company Overview

Technology Platform

Proprietary development and formulation of (Z)-endoxifen, a potent selective estrogen receptor modulator (SERM) designed to be nearly 100 times more potent than other SERMs with a potentially improved tolerability profile.

Pipeline Snapshot

5 drugs in pipeline

Drug	Indication	Stage
Fulvestrant	Female Breast Carcinoma	Phase 2
Z-Endoxifen + Placebo	Breast Density	Phase 2
(Z)-endoxifen + goserelin	Breast Neoplasms	Phase 2
Topical endoxifen + Placebo	Mammographic Breast Density	Phase 2
AT-301B + AT-301A	Healthy	Phase 1

Opportunities

The primary growth opportunity is the successful development and commercialization of (Z)-endoxifen across multiple breast cancer settings, particularly in metastatic disease where unmet need is high.

Success could lead to expansion into adjuvant treatment for early-stage cancer and potentially into prevention for high-risk individuals, accessing multi-billion dollar market segments.

Risk Factors

Key risks include clinical trial failure of its sole lead asset, intense competition from established and novel breast cancer therapies, dependence on raising additional capital as a pre-revenue company, and regulatory hurdles that could delay or prevent approval.

Competitive Landscape

Atossa competes in the crowded breast cancer market against generic endocrine therapies, novel oral SERDs, CDK4/6 inhibitors, and targeted agents. Its differentiation is based on the claimed superior potency and potentially improved tolerability of (Z)-endoxifen compared to existing SERMs like tamoxifen.